Announcement • Jul 21
QScreen AI Inc. Completes Tiered Screening Architecture And Demonstrates Escalation-Based Review Capability QScreen AI Inc. announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated near-term milestone. The milestone marks the fourth build milestone the Company has delivered in as many months: full platform integration across its three signal modalities in April, passive voice analysis in May, the grant of US Patent No. 12,640,164 announced last week, and now the tiered architecture that turns the patented method into a deployable institutional product. Under the tiered model, every worker passes through a rapid readiness gate of approximately 90 seconds, running on the Company's patented single-camera method on hardware the site already owns, a standard laptop or tablet with a webcam, in a browser, with no installation project. Clear results clear and only ambiguous results escalate to an extended assessment. The escalation tier is what makes the architecture different. Rather than re-running the same test, the extended assessment measures different abilities: smooth-pursuit eye tracking, response inhibition, and sustained attention. It is offered once per session, under site-configured policy, and it is not an appeal. A second-stage result can corroborate or contextualize a first-stage concern, but it can never overturn it. Certain safety-critical signals bypass escalation entirely and route directly to a person. Every step, both stages, and the final human decision are logged to a session record and presented side by side in the platform's supervisor console. The design encodes a principle the Company believes will define this category: the software flags, gathers evidence, and documents; a trained supervisor or licensed professional decides. No worker is ever stood down by an algorithm. The architecture is built for the arithmetic of a real shift change. A comprehensive assessment run on every worker at every shift is operationally impossible at scale; a 90-second gate for everyone, with extended assessment reserved for ambiguous results, screens an entire workforce within normal shift-start windows while spending measurement time exactly where the signal needs it. For the worker, the escalation tier functions as structured due process: an ambiguous result earns a fuller, fairer look before any supervisor conversation begins, uniformly applied and fully documented. The Company's engagement with Global Frontier Advisors has produced a concentrated pipeline of prospective institutional and industrial evaluators in the southeastern United States. The tiered architecture also underpins the Company's commercial model, with site licensing structured around workforce coverage rather than per-test counts, as shared with its US channel partners. QScreen AI screening tools provide risk assessment and decision support only. They are not diagnostic medical devices and are not intended to replace professional medical judgment. Announcement • Feb 27
QScreen AI Inc. announced that it expects to receive CAD 0.5 million in funding QScreen AI Inc. announced a non-brokered private placement up to 10,000,000 units at a price of CAD 0.05 per Unit, for aggregate gross proceeds to the Company of up to CAD 500,000 on February 26, 2026. Each Unit will be comprised of one common share of the Company and one half of one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one half Common Share of the Company at a price of CAD 0.15 for a period of 36 months following the closing date of the Offering. If, following four months and a day after the Closing Date, the volume weighted average price of the Common Shares on the CSE is equal to or greater than CAD 0.30 for any 10 consecutive trading days, the Corporation may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice. New Risk • Dec 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 36% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Negative equity (-CA$905k). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$14.3m market cap, or US$10.2m). 
